Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.

Pancreatic cancer (PC) remains one of the most lethal human malignancies with poor prognosis. Despite all advances in preclinical research, there have not been significant translation of novel therapies into the clinics. The development of genetically engineered mouse (GEM) models that produce spont...

Full description

Bibliographic Details
Main Authors: María P Torres, Satyanarayana Rachagani, Joshua J Souchek, Kavita Mallya, Sonny L Johansson, Surinder K Batra
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3835415?pdf=render
_version_ 1828865274709803008
author María P Torres
Satyanarayana Rachagani
Joshua J Souchek
Kavita Mallya
Sonny L Johansson
Surinder K Batra
author_facet María P Torres
Satyanarayana Rachagani
Joshua J Souchek
Kavita Mallya
Sonny L Johansson
Surinder K Batra
author_sort María P Torres
collection DOAJ
description Pancreatic cancer (PC) remains one of the most lethal human malignancies with poor prognosis. Despite all advances in preclinical research, there have not been significant translation of novel therapies into the clinics. The development of genetically engineered mouse (GEM) models that produce spontaneous pancreatic adenocarcinoma (PDAC) have increased our understanding of the pathogenesis of the disease. Although these PDAC mouse models are ideal for studying potential therapies and specific genetic mutations, there is a need for developing syngeneic cell lines from these models. In this study, we describe the successful establishment and characterization of three cell lines derived from two (PDAC) mouse models. The cell line UN-KC-6141 was derived from a pancreatic tumor of a Kras(G12D);Pdx1-Cre (KC) mouse at 50 weeks of age, whereas UN-KPC-960 and UN-KPC-961 cell lines were derived from pancreatic tumors of Kras(G12D);Trp53(R172H);Pdx1-Cre (KPC) mice at 17 weeks of age. The cancer mutations of these parent mice carried over to the daughter cell lines (i.e. Kras(G12D) mutation was observed in all three cell lines while Trp53 mutation was observed only in KPC cell lines). The cell lines showed typical cobblestone epithelial morphology in culture, and unlike the previously established mouse PDAC cell line Panc02, expressed the ductal marker CK19. Furthermore, these cell lines expressed the epithelial-mesenchymal markers E-cadherin and N-cadherin, and also, Muc1 and Muc4 mucins. In addition, these cell lines were resistant to the chemotherapeutic drug Gemcitabine. Their implantation in vivo produced subcutaneous as well as tumors in the pancreas (orthotopic). The genetic mutations in these cell lines mimic the genetic compendium of human PDAC, which make them valuable models with a high potential of translational relevance for examining diagnostic markers and therapeutic drugs.
first_indexed 2024-12-13T04:25:45Z
format Article
id doaj.art-3928ceba54c24f05ad6476142ef13e6c
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T04:25:45Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-3928ceba54c24f05ad6476142ef13e6c2022-12-21T23:59:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01811e8058010.1371/journal.pone.0080580Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.María P TorresSatyanarayana RachaganiJoshua J SouchekKavita MallyaSonny L JohanssonSurinder K BatraPancreatic cancer (PC) remains one of the most lethal human malignancies with poor prognosis. Despite all advances in preclinical research, there have not been significant translation of novel therapies into the clinics. The development of genetically engineered mouse (GEM) models that produce spontaneous pancreatic adenocarcinoma (PDAC) have increased our understanding of the pathogenesis of the disease. Although these PDAC mouse models are ideal for studying potential therapies and specific genetic mutations, there is a need for developing syngeneic cell lines from these models. In this study, we describe the successful establishment and characterization of three cell lines derived from two (PDAC) mouse models. The cell line UN-KC-6141 was derived from a pancreatic tumor of a Kras(G12D);Pdx1-Cre (KC) mouse at 50 weeks of age, whereas UN-KPC-960 and UN-KPC-961 cell lines were derived from pancreatic tumors of Kras(G12D);Trp53(R172H);Pdx1-Cre (KPC) mice at 17 weeks of age. The cancer mutations of these parent mice carried over to the daughter cell lines (i.e. Kras(G12D) mutation was observed in all three cell lines while Trp53 mutation was observed only in KPC cell lines). The cell lines showed typical cobblestone epithelial morphology in culture, and unlike the previously established mouse PDAC cell line Panc02, expressed the ductal marker CK19. Furthermore, these cell lines expressed the epithelial-mesenchymal markers E-cadherin and N-cadherin, and also, Muc1 and Muc4 mucins. In addition, these cell lines were resistant to the chemotherapeutic drug Gemcitabine. Their implantation in vivo produced subcutaneous as well as tumors in the pancreas (orthotopic). The genetic mutations in these cell lines mimic the genetic compendium of human PDAC, which make them valuable models with a high potential of translational relevance for examining diagnostic markers and therapeutic drugs.http://europepmc.org/articles/PMC3835415?pdf=render
spellingShingle María P Torres
Satyanarayana Rachagani
Joshua J Souchek
Kavita Mallya
Sonny L Johansson
Surinder K Batra
Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
PLoS ONE
title Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
title_full Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
title_fullStr Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
title_full_unstemmed Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
title_short Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
title_sort novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma applications in diagnosis and therapy
url http://europepmc.org/articles/PMC3835415?pdf=render
work_keys_str_mv AT mariaptorres novelpancreaticcancercelllinesderivedfromgeneticallyengineeredmousemodelsofspontaneouspancreaticadenocarcinomaapplicationsindiagnosisandtherapy
AT satyanarayanarachagani novelpancreaticcancercelllinesderivedfromgeneticallyengineeredmousemodelsofspontaneouspancreaticadenocarcinomaapplicationsindiagnosisandtherapy
AT joshuajsouchek novelpancreaticcancercelllinesderivedfromgeneticallyengineeredmousemodelsofspontaneouspancreaticadenocarcinomaapplicationsindiagnosisandtherapy
AT kavitamallya novelpancreaticcancercelllinesderivedfromgeneticallyengineeredmousemodelsofspontaneouspancreaticadenocarcinomaapplicationsindiagnosisandtherapy
AT sonnyljohansson novelpancreaticcancercelllinesderivedfromgeneticallyengineeredmousemodelsofspontaneouspancreaticadenocarcinomaapplicationsindiagnosisandtherapy
AT surinderkbatra novelpancreaticcancercelllinesderivedfromgeneticallyengineeredmousemodelsofspontaneouspancreaticadenocarcinomaapplicationsindiagnosisandtherapy